SRZN
HealthcareSurrozen, Inc.
$19.10
$-2.45 (-11.37%)
Jan 5, 2026
Price History (1Y)
Analysis
Surrozen, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $163.71 million and approximately 40 employees. The company operates in the industry of biotechnology. Financially, Surrozen has reported a revenue of $3.60 million for the trailing twelve months, which represents a year-over-year decline of -90.2%. However, the company's operating margin is -1107.3% and its profit margin is 0.0%, indicating significant losses. The net income for the trailing twelve months is -$86,906,000, and the company has negative EBITDA and free cash flow. Surrozen has a substantial amount of cash on hand at $81.33 million but also carries debt worth $7.08 million. In terms of valuation, the forward P/E ratio is -3.99, and the price to book ratio is -6.96. The company's price to sales ratio is 45.43, indicating a relatively high valuation multiple compared to its peers. The beta value is 0.58, suggesting that Surrozen's stock price movements are moderately correlated with the broader market.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Surrozen, Inc.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $163.71M
- P/E Ratio
- N/A
- 52-Week High
- $24.94
- 52-Week Low
- $5.90
- Avg Volume
- 81.17K
- Beta
- 0.58
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 40